Second Amendment To Collaboration and License AgreementCollaboration and License Agreement • March 3rd, 2022 • Wave Life Sciences Ltd. • Pharmaceutical preparations
This Second Amendment (this “Second Amendment”) to the Collaboration Agreement (as defined below) is entered into as of October 15, 2021 (“Second Amendment Effective Date”) by and among Wave Life Sciences USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Wave US”), Wave Life Sciences UK Limited, a private limited company incorporated under the laws of England and Wales (“Wave UK”, and together with Wave US, “Wave”), and Takeda Pharmaceutical Company Limited, a corporation organized and existing under the Laws of Japan (“Takeda”). Wave and Takeda are referred to in this Agreement individually as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein will have the meanings ascribed to them in the Collaboration Agreement.
